182 related articles for article (PubMed ID: 38195686)
21. The Characterization of a Subependymal Giant Astrocytoma-Like Cell Line from Murine Astrocyte with mTORC1 Hyperactivation.
Tang X; Angst G; Haas M; Yang F; Wang C
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33923449
[TBL] [Abstract][Full Text] [Related]
22. Finding a cure for tuberous sclerosis complex: From genetics through to targeted drug therapies.
McEneaney LJ; Tee AR
Adv Genet; 2019; 103():91-118. PubMed ID: 30904097
[TBL] [Abstract][Full Text] [Related]
23. The specificity and role of microglia in epileptogenesis in mouse models of tuberous sclerosis complex.
Zhang B; Zou J; Han L; Beeler B; Friedman JL; Griffin E; Piao YS; Rensing NR; Wong M
Epilepsia; 2018 Sep; 59(9):1796-1806. PubMed ID: 30079598
[TBL] [Abstract][Full Text] [Related]
24. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
25. Prolonging the survival of Tsc2 conditional knockout mice by glutamine supplementation.
Rozas NS; Redell JB; McKenna J; Moore AN; Gambello MJ; Dash PK
Biochem Biophys Res Commun; 2015 Feb; 457(4):635-9. PubMed ID: 25613864
[TBL] [Abstract][Full Text] [Related]
26. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
[TBL] [Abstract][Full Text] [Related]
27. Rapamycin requires AMPK activity and p27 expression for promoting autophagy-dependent Tsc2-null cell survival.
Campos T; Ziehe J; Fuentes-Villalobos F; Riquelme O; Peña D; Troncoso R; Lavandero S; Morin V; Pincheira R; Castro AF
Biochim Biophys Acta; 2016 Jun; 1863(6 Pt A):1200-7. PubMed ID: 26975583
[TBL] [Abstract][Full Text] [Related]
28. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
[TBL] [Abstract][Full Text] [Related]
29. Pathology of hereditary renal cell carcinoma syndromes: Tuberous sclerosis complex (TSC).
Machacek ME; Wu CL; Cornejo KM
Semin Diagn Pathol; 2024 Jan; 41(1):8-19. PubMed ID: 37993384
[TBL] [Abstract][Full Text] [Related]
30. Rapalog resistance is associated with mesenchymal-type changes in Tsc2-null cells.
Valianou M; Filippidou N; Johnson DL; Vogel P; Zhang EY; Liu X; Lu Y; Yu JJ; Bissler JJ; Astrinidis A
Sci Rep; 2019 Feb; 9(1):3015. PubMed ID: 30816188
[TBL] [Abstract][Full Text] [Related]
31. Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β (RARβ).
Liu HJ; Lam HC; Baglini CV; Nijmeh J; Cottrill AA; Chan SY; Henske EP
Oncogene; 2019 Dec; 38(49):7367-7383. PubMed ID: 31420607
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
Mi R; Ma J; Zhang D; Li L; Zhang H
J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
[TBL] [Abstract][Full Text] [Related]
33. Equivalent benefit of rapamycin and a potent mTOR ATP-competitive inhibitor, MLN0128 (INK128), in a mouse model of tuberous sclerosis.
Guo Y; Kwiatkowski DJ
Mol Cancer Res; 2013 May; 11(5):467-73. PubMed ID: 23386687
[TBL] [Abstract][Full Text] [Related]
34. TSC patient-derived isogenic neural progenitor cells reveal altered early neurodevelopmental phenotypes and rapamycin-induced MNK-eIF4E signaling.
Martin P; Wagh V; Reis SA; Erdin S; Beauchamp RL; Shaikh G; Talkowski M; Thiele E; Sheridan SD; Haggarty SJ; Ramesh V
Mol Autism; 2020; 11(1):2. PubMed ID: 31921404
[TBL] [Abstract][Full Text] [Related]
35. A substrate-specific mTORC1 pathway underlies Birt-Hogg-Dubé syndrome.
Napolitano G; Di Malta C; Esposito A; de Araujo MEG; Pece S; Bertalot G; Matarese M; Benedetti V; Zampelli A; Stasyk T; Siciliano D; Venuta A; Cesana M; Vilardo C; Nusco E; Monfregola J; Calcagnì A; Di Fiore PP; Huber LA; Ballabio A
Nature; 2020 Sep; 585(7826):597-602. PubMed ID: 32612235
[TBL] [Abstract][Full Text] [Related]
36. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
[TBL] [Abstract][Full Text] [Related]
37. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
Liu HJ; Lizotte PH; Du H; Speranza MC; Lam HC; Vaughan S; Alesi N; Wong KK; Freeman GJ; Sharpe AH; Henske EP
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669930
[TBL] [Abstract][Full Text] [Related]
38. The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex.
Way SW; Rozas NS; Wu HC; McKenna J; Reith RM; Hashmi SS; Dash PK; Gambello MJ
Hum Mol Genet; 2012 Jul; 21(14):3226-36. PubMed ID: 22532572
[TBL] [Abstract][Full Text] [Related]
39. Not all kidney cysts are created equal: a distinct renal cystogenic mechanism in tuberous sclerosis complex (TSC).
Soleimani M
Front Physiol; 2023; 14():1289388. PubMed ID: 38028758
[TBL] [Abstract][Full Text] [Related]
40. Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing
Klover PJ; Thangapazham RL; Kato J; Wang JA; Anderson SA; Hoffmann V; Steagall WK; Li S; McCart E; Nathan N; Bernstock JD; Wilkerson MD; Dalgard CL; Moss J; Darling TN
Elife; 2017 Jul; 6():. PubMed ID: 28695825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
